Search
Filters
Clear All
  • 10

Phase

  • 1
  • 1
  • 1
  • 1
  • 6
  • 10
  • 1

Found 10 lauren-perrey-moore trials

A listing of lauren-perrey-moore medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

HEALEY ALS Platform: Multi-Center, Multi-Regimen clinical trial evaluating investigational products for the treatment of ALS

C
Cynthia Bodkin, MD
18-100 years
All genders
Interventional
ALS is a degenerative disorder of the nerves controlling movement (“motor neurons”). ALS causes muscles to become weak, which leads to paralysis. ALS is a condition that gradually damages the nerve cells in the brain and spinal cord.  Currently, there are no treatments to prevent, reverse, or stop the development of …
Learn More

Dominantly Inherited Alzheimer Network (DIAN)

M
Martin Farlow, MD
18-100 years
All genders
The overall purpose of this research is to understand the changes that occur in dominantly inherited Alzheimer disease.
Learn More

Alnylam ALN-APP-001: Phase I, placebo-controlled trial of ALN-APP in participants with Early-Onset Alzheimer’s disease

J
Jared Brosch, MD
18-100 years
All genders
Phase 1
Interventional
Who is Eligible Ages 18+ Must have had symptoms of Alzheimer’s disease prior to age 65 Diagnosis of Alzheimer’s disease Must be able to complete MRI Must be able to tolerate lumbar puncture No history of seizures, stroke or cancer in the last 5 years What is Involved In-person visits …
Learn More

Medicinova MN-166-ALS-2301, COMBAT-ALS: Phase 2b/3, placebo-controlled trial of MN-166/Ibudilast in participants with Amylotrophic Lateral Sclerosis (ALS)

C
Cynthia Bodkin, MD
18-80 years
All genders
Phase 2/3
Interventional
Who is Eligible Ages 18-80 Diagnosis of ALS with symptoms starting less than 18 months ago Able to swallow medication capsules No history of cancer within last 5 years No use of tracheostomy or almost continuous ventilator support What is Invovled In-person appointments at the IUH Neuroscience Center Participants will …
Learn More

Enroll-HD: Registry trial for participants with Huntington’s disease

C
Christopher James
All genders
Observational
The purpose of this study is to collect clinical information about patients and families with Huntington Disease. Who is Eligible Diagnosis of Huntington’s disease What is Involved In person at IUH Neuroscience Center Annual cognitive testing and blood work at routine clinic appointment.  
Learn More

Multi-center Development of a Novel Diagnostic Test for Alzheimer's Disease (DTAD Study)

M
Martin Farlow, MD
60-90 years
Healthy Volunteer
All genders
We are doing this research to test a new method of diagnosing Alzheimer’s Disease using a blood test and an injection of a diabetes drug called pramlintide. You will receive one dose of this medication at each of two visits. This study is conducted at three medical centers in Indianapolis …
Learn More

Parkinson’s Foundation PD GENEration Genetic Registry

S
S. Elizabeth Zauber
18-100 years
All genders
Who is Eligible Ages 18+ Diagnosis of Parkinson’s disease Willingness to undergo genetic testing What is Involved In person at IUH Neuroscience Center or kit can be mailed to participant’s home Genetic testing occurs via buccal swab or blood draw in clinic or at home, participants receive genetic counseling  
Learn More

Phase II, placebo-controlled trial of SAGE-718 on cognitive function in participants with Huntington’s disease

C
Christopher James
25-65 years
All genders
Phase 2
Interventional
Who is Eligible Ages 25-65 Diagnosis of Huntington’s disease Able to swallow pills and liquids No history of cancer within last 12 months No current substance or alcohol abuse (including THC) No history of stroke or head injury requiring hospitalization What is Involved In person at IUH Neuroscience CenterDaily oral …
Learn More

Development of trial-ready cohort to facilitate rapid enrollment into Alzheimer’s trials for participants with Down Syndrome (Trial Ready Cohort—Down Syndrome (TRC-DS)

J
Jill Fodstad
35-55 years
All genders
Interventional
Who is Eligible Ages 35-55 Must be willing to complete PET scan What is Involved Onsite visits at the IUH Neuroscience Center Visits at the IUH Neuroscience Center every 16 months Compensation Compensation available via payment card for each completed appointment
Learn More

AHEAD 3-45 Study: Phase III, placebo-controlled trial of Lecanemab in participants with preclinical Alzheimer’s disease

M
Martin Farlow, MD
55-80 years
All genders
Phase 3
Interventional
The purpose of this study is to determine whether treatment with BAN2401 is superior to placebo on change from baseline of the Preclinical Alzheimer’s disease (AD) Cognitive Composite 5 (PACC5) at 216 weeks of treatment Who is Eligible Ages 55-80 No diagnosis of mild cognitive impairment or Alzheimer’s disease No …
Learn More